Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!

Area of Science:

• Pharmacology
• Neurology
• Cardiology

Background:

• Sacubitril/valsartan (LCZ696) is an angiotensin receptor-neprilysin inhibitor (ARNI) approved for heart failure (HF).
• Neprilysin inhibition by sacubitril has complex effects, including cardiovascular benefits and potential adverse neurological impacts.
• Hypertensive heart failure (HHF) is a key indication for this ARNI therapy.

Purpose of the Study:

• To review existing experimental and clinical data on neprilysin inhibitors and their association with dementia-related side effects.
• To assess the potential risk of memory and cognitive dysfunction linked to sacubitril/valsartan (LCZ696).
• To determine the need for further investigation into LCZ696's impact on brain health, specifically beta-amyloid (Aβ) degradation.

Main Methods:

• Literature review of experimental and clinical studies.
• Analysis of data concerning neprilysin inhibitors and cognitive side effects.
• Examination of evidence regarding LCZ696's safety profile for brain function.

Main Results:

• Evidence suggests LCZ696 may elevate the risk of memory and cognitive impairments.
• Current clinical trials lack robust data demonstrating the brain safety of LCZ696.
• Potential exacerbation of Alzheimer's disease (AD) by neprilysin inhibition is a concern.

Conclusions:

• Further experimental and clinical studies are essential to evaluate LCZ696's cognitive safety.
• Specific focus on LCZ696's effects on beta-amyloid (Aβ) degradation is required.
• Long-term administration safety for cognitive function remains uncertain and warrants investigation.